Glucose Homeostasis

Glucose Homeostasis

Glucose homeostasis is the tightly controlled system that keeps blood sugar within a normal range of about 70–140 mg/dL through the day. It depends on insulin from pancreatic beta cells, glucagon from alpha cells, glucose output from the liver, glucose uptake by muscle and other tissues, and incretin hormone signals from the gut. When the system works well, blood sugar rises a little after meals and returns to baseline within a few hours, giving a steady supply of energy to tissues that rely on glucose, such as the brain.

A breakdown in glucose homeostasis is the hallmark of type 2 diabetes and prediabetes. Insulin resistance in muscle, liver and fat tissue makes insulin less effective at clearing glucose from the blood, while beta cells gradually fail and cannot compensate. Over time, fasting and after-meal glucose levels rise, leading to chronic high blood sugar and its complications, including cardiovascular disease and damage to the kidneys, nerves and eyes.

Retatrutide’s triple agonist action works on glucose homeostasis through several complementary pathways. GLP-1 receptor activation boosts glucose-dependent insulin release and curbs unneeded glucagon release. GIP receptor activation boosts insulin release further and may improve beta cell function. Glucagon receptor activation raises energy use and fat burning in the liver, which indirectly improves insulin sensitivity. In Phase 2 trials, retatrutide lowered HbA1c by up to 2.02% in people with type 2 diabetes, a sign of large improvements in overall glucose control.